Contrast echocardiography: What have we learned from the new guidelines?

Current Cardiology Reports

Volumn 12, Issue 3, 2010, Pages 237-242

  Wei, Kevin ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Clinical applications; Contrast agents; Contrast echocardiography; New guidelines

Indexed keywords

ECHO CONTRAST MEDIUM; PERFLUTREN; SONOVUE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANAPHYLAXIS; BRADYCARDIA; CONTRAST ECHOCARDIOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DOPPLER ECHOCARDIOGRAPHY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INFORMATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HEART ARREST; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE VOLUME; HEART TUMOR; HUMAN; HYPOTENSION; INTERMETHOD COMPARISON; INTRACARDIAC THROMBOSIS; MEDICAL ASSESSMENT; MEDICAL LITERATURE; MEDICAL SOCIETY; PATIENT SAFETY; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PREDICTION; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRESS ECHOCARDIOGRAPHY; THREE DIMENSIONAL IMAGING; TRANSTHORACIC ECHOCARDIOGRAPHY;

CONSENSUS; CONTRAST MEDIA; ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY, DOPPLER; HEART VENTRICLES; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; STROKE VOLUME; SYSTOLE; VENTRICULAR FUNCTION, LEFT;

EID: 77956395408     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-010-0105-x     Document Type: Review

References (12)

1. Mulvagh SL, Rakowski H, Vannan MA, et al.: American Society of Echocardiography consensus statement on the clinical applications of ultrasonic contrast agents in echocardiography. J Am Soc Echocardiogr 2008, 21:1179-1201. This consensus statement provides the most current recommendations on contrast utilization during echocardiography.
2. Mulvagh SL, DeMaria AN, Feinstein SB, et al.: Contrast echocardiography: Current and future applications. J Am Soc Echocardiogr 2000, 13:331-342.
3. Kurt M, Shaikh KA, Peterson L, et al.: Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. J Am Coll Cardiol 2009, 53:802-810.
4. Cosyns B, Haberman D, Droogmans S, et al.: Comparison of contrast enhanced three dimensional echocardiography with MIBI gated SPECT for the evaluation of left ventricular function. Cardiovasc Ultrasound 2009, 7:27-36.
5. Mansencal N, Nasr IA, Pilliere R, et al.: Usefulness of contrast echocardiography for assessment of left ventricular thrombus after acute myocardial infarction. Am J Cardiol 2007, 99:1667-1670.
6. Nemes A, Geleijnse ML, Krenning BJ, et al.: Usefulness of ultrasound contrast agent to improve image quality during realtime three-dimensional stress echocardiography. Am J Cardiol 2007, 99:275-278.
7. Wyrick JJ, Kalvaitis S, McConnell J, et al.: Cost-efficiency of myocardial contrast echocardiography in patients presenting to the emergency department with chest pain of suspected cardiac origin and a nondiagnostic electrocardiogram. AmJ Cardiol 2008, 102:649-652.
8. Wei K, Mulvagh SL, Carson L, et al.: The Safety of definity and optison for ultrasound image enhancement: A retrospective analysis of 78,383 administered contrast doses. J Am Soc Echocardiogr 2008, 11:1202-1206. This study is one of the largest retrospective analyses evaluating the safety of ultrasound contrast agents.
9. Kusnetzky LL, Khalid A, Khumri TM, et al.: Acute mortality in hospitalized patients undergoing echocardiography with and without ultrasound contrast agent. Results in 18,671 consecutive studies. J Am Coll Cardiol 2008, 51:1704-1706.
10. Main ML, Ryan AC, Davis TE, et al.: Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (multicenter registry results in 4,300,966 consecutive patients). Am J Cardiol 2008, 102:1742-1746.
11. European Medicines Agency: European public assessment report (EPAR) SonoVue. 2007. Available at http://www.emea.europa.eu/ humandocs/PDFs/EPAR/ sonovue/005301en1.pdf. Accessed February 2010.
12. US Food and Drug Administration: FDA Alert: Information for healthcare professionals. Micro-bubble contrast agents (marketed as Definity (perflutren lipid microsphere) injectable suspension and Optison (perflutren protein-type a microspheres for injection. 2008. Available at http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrug SafetyInformationforPatientsandProviders/ucm125574. htm. Assessed February 2010.